论文部分内容阅读
Combination therapy is an emerging strategy that is under intensive preclinical investigation for the treatment of various diseases(1).CD98 is highly overexpressed on the surfaces of epithelial cells and macrophages in the colon tissue with ulcerative colitis(UC),which is usually associated with mucosal damage and inflammation.We previously proved that CD98 siRNA(siCD98)-induced down-regulation of CD98 in colitis tissue decreased the severity of UC to a certain extent(2).In an effort to further improve the therapeutic efficacy,we aim to simultaneously deliver siCD98 in combination with a potent anti-inflammatory agent,curcumin(CUR),using hyaluronic acid(HA)-functionalized polymeric nanoparticles(NPs).